← back to search

Michael G. Silverman

Harvard University · US
Area of research
Emergency Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Cardiac Arrest and Resuscitation, Cardiac Imaging and Diagnostics, Heart Failure Treatment and Management, and Mechanical Circulatory Support Devices.
h-index
27
citations
11,034
works
75
NIH funding
primary concept
Medicine
email

Recent publications

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Circulation 2019cited by 559position: middledoi
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine 2018cited by 6,242position: middledoi
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
American Heart Journal 2018cited by 182position: middledoi
<scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics
Diabetes Obesity and Metabolism 2018cited by 112position: middledoi
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
JAMA 2016cited by 1,459position: firstdoi
The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)
Atherosclerosis 2015cited by 208position: middledoi
Use of Coronary Artery Calcium Testing to Guide Aspirin Utilization for Primary Prevention: Estimates From the Multi-Ethnic Study of Atherosclerosis
Circulation Cardiovascular Quality and Outcomes 2014cited by 238position: middledoi
Association of Coronary Artery Calcium and Coronary Heart Disease Events in Young and Elderly Participants in the Multi-Ethnic Study of Atherosclerosis
Mayo Clinic Proceedings 2014cited by 113position: middledoi
Potential Implications of Coronary Artery Calcium Testing for Guiding Aspirin Use Among Asymptomatic Individuals With Diabetes
Diabetes Care 2012cited by 51position: firstdoi

Grants

Genetic Regulation of Bioluminescence in Marine Bacteria
NSF9419862$315,0001995–1997PIRePORTER
Genetic Regulation of Bioluminescence in Marine Bacteria
NSF9200028$285,0001992–1995PIRePORTER
Genetic Regulation of Bioluminescence in Marine Bacteria
NSF8820665$327,8001989–1992PIRePORTER
Genetic Regulation of Bioluminescence in Marine Bacteria
NSF8507874$300,0001985–1989PIRePORTER
Near Eastern Epigraphy
NSF7800557$28,0801977–1979PIRePORTER
Near Eastern Epigraphy
NSF7714506$28,0001977–1979PIRePORTER

Frequent collaborators

Marc S. Sabatine · Smart Material (Germany)5 papers (2016–2019)Stephen D. Wiviott · Brigham and Women's Hospital5 papers (2016–2019)John Wilding · University of Liverpool4 papers (2018–2019)Avivit Cahn · Hadassah Medical Center4 papers (2018–2019)Peter A. Johansson · QIMR Berghofer Medical Research Institute4 papers (2018–2019)Darren K. McGuire · Saint Luke's Health System4 papers (2018–2019)Khurram Nasir · Houston Methodist4 papers (2012–2015)Matthew J. Budoff · Phoenix (United States)4 papers (2012–2015)Lawrence A. Leiter · St. Michael's Hospital4 papers (2018–2019)Ofri Mosenzon · Hadassah Medical Center4 papers (2018–2019)Marc P. Bonaca · Amsterdam University Medical Centers4 papers (2018–2019)Eri Kato · Hiroshima University4 papers (2018–2019)Ingrid Gause‐Nilsson · AstraZeneca (Switzerland)4 papers (2018–2019)Michael J. Blaha · University of Pittsburgh Medical Center4 papers (2012–2015)Deepak L. Bhatt · Technische Universität Dresden4 papers (2018–2019)Itamar Raz · Thrombolysis in Myocardial Infarction Study Group3 papers (2018–2019)Roger S. Blumenthal · Yale University3 papers (2012–2015)Anna Maria Langkilde · AstraZeneca (Brazil)3 papers (2018–2019)Ron Blankstein · Harvard University3 papers (2014–2015)Thomas A. Zelniker · Thrombolysis in Myocardial Infarction Study Group2 papers (2018–2019)